Compositions comprising butyric acid and gluconic acid for treatment of disorders and syndromes associated with intestinal barrier dysfunction and dysbiosis
By combining butyrate and gluconic acid in a specific ratio, the problems of ineffective probiotic and prebiotic combinations and intestinal discomfort have been solved, resulting in a significant improvement in intestinal anti-inflammatory activity and intestinal barrier function, making it suitable for the treatment of a variety of intestinal diseases.
Patent Information
- Application Number
- CN202380022207.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-02
- Filing Date
- 2023-03-01
- Publication Date
- 2024-11-01
AI Technical Summary
Existing technologies for regulating intestinal inflammation have several drawbacks: the combination of probiotics and prebiotics does not have a significant synergistic effect; prebiotic fiber may lead to increased fermentation and intestinal discomfort; probiotics may be ineffective or harmful in unstable intestinal mucosa conditions; and the oral form of butyrate has unacceptable odor and sour taste.
Butyric acid or its salts are combined with gluconic acid in a specific ratio, ranging from 4:1 to 60:1, preferably from 10:1 to 25:1, to prepare functional foods, pharmaceutical forms, etc., and specific technologies are used to ensure that butyrate is released in the colon, reducing unpleasant odors and tastes.
It significantly increases intestinal anti-inflammatory activity, improves intestinal barrier function, and reduces intestinal discomfort. It is suitable for the treatment of irritable bowel syndrome, chronic inflammatory bowel disease, etc., avoiding the limitations of combinations of probiotics and prebiotics, and providing safe and effective anti-inflammatory effects.
Smart Images

Figure BDA0004996197840000101 
Figure BDA0004996197840000111 
Figure BDA0004996197840000141
Abstract
Description
[0001] The present invention relates to a composition comprising butyric acid or a salt thereof and gluconic acid, which can be used to treat disorders and syndromes associated with intestinal barrier dysfunction and dysbiosis. Prior art
[0002] Intestinal changes are often associated with a state of low-grade chronic inflammation that characterizes intestinal changes and further exacerbates the state of the intestine, in a vicious cycle in which it is difficult to determine whether inflammation is a cause or a consequence.
[0003] Several factors trigger and feed the low-grade inflammatory state and are usually combined in a multifactorial process: - dietary habits (Western diet, consumption of processed foods, alcohol, etc.),
[0004] -Continuous stress,
[0005] - intestinal dysbiosis (long-term antibiotic or cortisone treatment, previous infection, etc.),
[0006] - Lifestyle (sedentary habits, abuse of laxatives),
[0007] -Changes in circadian rhythms.
[0008] The persistence of a low-grade chronic inflammatory state alters intestinal permeability (leaky gut) and intestinal barrier function, causes overactivation of the intestinal immune system, and causes changes in the intestinal microbiota, all of which lead to further exacerbations with local reactions (constipation, diarrhea, flatulence, malabsorption) and systemic reactions (fatigue, reduced immune defenses, skin diseases, food intolerance, urinary tract infections, and metabolic disorders) [Konig et al., 2016].
[0009] Acute or chronic inflammation and altered intestinal barrier characterize a range of gastrointestinal and other disorders: IBS, IBD, diverticular disease / diverticulitis, food intolerances, recurrent cystitis, psoriasis, atopic dermatitis, changes in mood and general mental / physical health, etc.
[0010] Therefore, there is a growing interest in investigating effective solutions to control and modulate intestinal inflammatory processes, most of which involve attempts to modulate the intestinal microbiota, which is closely associated with alterations in inflammation and permeability.
[0011] Without a doubt, the largest market is probiotics, i.e. microorganisms (bacteria, yeasts) that, when consumed in adequate amounts, exert beneficial functions on the body primarily by producing metabolites that mediate their beneficial effects.
[0012] Probiotics can be used in various situations to compensate for microbial deficiencies and rebalance the intestinal flora, restoring the normal production of metabolites, but some limitations are generally recognized: dosage, viability and ability to colonize the intestine, where they are required to perform their functions and persistence. Recent attention has also focused on other key factors during the use of probiotics, especially strain-specific effects (only specific strains are effective in specific situations) and the need to focus more on safety. The integration of probiotic microorganisms is generally considered safe, and this is also true for most probiotic strains. However, although probiotics may be safe for healthy adults, their use is associated with a higher risk of infection and / or morbidity in some delicate situations: very low birth weight infants and infants, critically ill adults and pediatric patients in intensive care units, and postoperative, hospitalized or immunocompromised patients [Suez et al., 2019].
[0013] Other products on the market promote the use of prebiotic fibers (inulin, FOS, GOS), i.e. dietary fibers that promote the growth and development of the intestinal microbiota, with the aim of helping to eliminate dysbiosis and thus controlling inflammation by indirect mechanisms. There are also many products in which probiotics and prebiotics (synbiotics) are combined. There is also a large literature on the use of prebiotic fibers, but again their limitations are recognized, in particular the need to use them in large quantities (grams) for their benefit to be evident, the need for caution in patients with abdominal pain, as it can be enhanced by promoting fermentation processes, and their non-specific effects, as prebiotic fibers can act as nutrition for both "good" and "bad" bacterial flora.
[0014] In unstable conditions of the intestinal mucosa (e.g. leaky gut), especially in the colon, the administration of probiotic species, in the absence of adequate conditions for adhesion to the wall and replication, may be useless and often harmful due to the risk that the microbial species may penetrate the loose mesh of the intestinal barrier in the underlying tissue, thereby triggering dangerous defense mechanisms that produce an inflammatory state that is first local and then systemic.
[0015] In this case, even providing prebiotic fibers to stimulate the growth and metabolism of the species may be insufficient or even counterproductive, because in order to produce a prebiotic effect, the fibers must be provided in a dose of not less than a few grams, usually not less than 5 g, and preferably 15-20 g per day, which can become a nutrient substrate for bacterial species that are harmful to humans. Gluconate is also used as a prebiotic, which stimulates butyrate production in the large intestine and avoids digestion and absorption in the small intestine, and more than 70% of the gluconic acid introduced with the diet or dietary supplement reaches the large intestine. There, gluconic acid is fermented by various bacteria (Lactobacillus and Bifidobacterium) that form lactate and acetate, which are in turn converted to butyrate by bacteria such as Megasphaera elsdenii. A study conducted on an animal model suggests that continuous intake of gluconic acid promotes the production of butyrate in the large intestine. These findings suggest that gluconic acid is a useful prebiotic that may contribute to health by producing butyrate in the large intestine. The beneficial health effects of prebiotic compounds are apparently dependent on the presence of suitable bacterial species to ferment them [Tsukahara et al., 2002; Kameue et al., 2004; Kameue et al., 2006], and gluconic acid, like other prebiotics, must be taken in amounts of several grams, e.g. 3g-9g per day, in order to have a significant effect on human health [Asano et al., 1994].
[0016] Recent studies evaluating the effects of probiotics and prebiotics, alone and in combination, on intestinal barrier function in obese patients have shown that the administration of probiotics and prebiotics alone improves the barrier function of the intestine, but that the combination of probiotics and prebiotics does not produce any significant synergistic effects [Krumbeck et al., 2018]. Even more recently, a study retrospectively examining data from a group of 438 patients undergoing immunotherapy for metastatic melanoma was published in Science [Spencer et al., 2021], where the treatment response to immunotherapy could be radiologically assessed in 293 patients. The response was favorable in 193 people. In this “responder” subgroup, the 128 who had the greatest fiber intake in their diet had the best response to treatment. To determine whether there was a causal relationship, fiber intake was experimentally modulated in preclinical models, and it was confirmed that the group provided with a diet with a high fiber content responded significantly better to immunotherapy than the control group, as observed in patients. However, without the use of probiotics, the most significant benefits were observed in patients with adequate fiber intake in their diet.
[0017] Therefore, it may be useful to seek alternative solutions to modulate inflammatory processes to control intestinal discomfort. A recent option is to use the epigenetic metabolite butyrate, a short-chain fatty acid (SCFA) that is usually produced by the fermentation of prebiotic fibers by intestinal bacteria. Butyrate is the main energy source for colonocytes, meeting about 60-70% of the energy requirements and helping to maintain intestinal homeostasis. Regarding its regulatory functions, although their mechanism of action has not yet been elucidated, butyrate is clearly able to affect cellular function through genetic and epigenetic regulatory processes [Fu et al., 2019]. Most of the beneficial effects of probiotics are attributed to butyrate, especially in controlling inflammation and barrier function. Butyrate is involved in a series of metabolic processes that modulate inflammation: it modulates the resident bacterial flora, improves epithelial barrier function, and modulates immune responses [Salminen et al., 2021]. One of the mechanisms by which butyrate can act as an anti-inflammatory agent is to inhibit the NF-KB transcription factor as a result of inhibiting histone deacetylase (HDAC) [Inan et al., 2000]. Butyrate can also directly activate GPCRs (G protein-coupled receptors) to maintain the balance between tolerance to commensal bacteria and immunity to pathogens in the intestinal immune system [Koh et al., 2016; Singh et al., 2014]. Butyrate also regulates transepithelial ion transport, affects intestinal motility and satiety by increasing the expression of peptide YY and proglucagon, and regulates brain function through epigenetic mechanisms that increase the proportion of intestinal cholinergic neurons. Recent studies have shown that butyrate supplementation has beneficial effects on health by reducing adipose tissue deposition and increasing insulin sensitivity [Fu et al., 2018].
[0018] In order for butyrate to be taken orally to perform any function, the need for butyrate to be delivered directly into the colon, where it performs its effects, which are mainly mediated by colonocytes, must be considered. If this were not the case, butyrate would be reused by cells of other tissues as a readily available energy source. For this reason, colonic release forms using specific technologies (delayed release, microencapsulation) are preferred. In addition, butyrate has a rather unpleasant odor and sour taste, so technical measures are also needed to eliminate this problem.
[0019] The anti-inflammatory properties of Manuka honey, a honey derived from the flowers of Leptospermum scoparium, are described by Prakash A. et al. in "Effect of different doses of Manuka honey inexperimentally induced inflammatory bowel disease in rats" Physiotherapy Research, 2008, 22(11), pp 1511-1519 and Aidan G Leong in "Indigenous New Zealand honeys exhibit multiple anti-inflammatory activities", Innate Immun 2012 Jun;18(3):459-66. Manuka honey contains mainly polyphenols as well as many other compounds. They include methylglyoxal, which is considered to be one of the components primarily responsible for its well-known antibacterial and anti-inflammatory properties. It also contains more than 30 organic acids, including butyric acid. The known activities of Manuka honey apparently do not suggest the usefulness of a particular combination of butyric acid and gluconic acid in a particular ratio.
[0020] CN 103806773, at least according to the available automatic translation, cites "sodium di-sec-octylsulfonate dibutyrate" and "stearic acid gluconolactone" as ingredients of food additives. The terminology is clearly unclear and does not allow the identity of the compounds cited to be determined; "stearic acid gluconolactone" is clearly completely meaningless, while "sodium di-sec-octylsulfonate dibutyrate" probably refers to "sodium di-sec-octyl dibutyrate sulfonate" according to the best assumption. However, even apart from the incorrect terminology, it is obvious that CN 103806773 does not describe the combination of butyric acid and gluconic acid in any way.
[0021] Description of the Invention
[0022] The present invention provides a composition with improved anti-inflammatory activity, which uses ingredients known in the field of nutrition / dietary and which are therefore considered safe, without significant side effects, and which specifically treats acute intestinal diseases, the therapeutic management of which is complicated by inflammatory components, even at a low level. At the same time, the present invention aims to overcome the limitations and critical factors associated with the use of conventional products, which are mainly based on the use of probiotics, prebiotics or synbiotic compositions.
[0023] The object is achieved by the combination of butyric acid or its salts with gluconic acid in a ratio that leads to a surprising increase in anti-inflammatory activity in the intestine, independently of the state of ecological balance or different degrees of intestinal dysbiosis.
[0024] Therefore, an object of the present invention is a pharmaceutical or nutritional composition comprising butyric acid or a salt thereof and gluconic acid or a salt thereof in a weight ratio ranging between 4:1-60:1, preferably between 10:1-25:1, more preferably 11:1-23:1.
[0025] Butyric acid can be used as such or in the form of a salt, such as a sodium, potassium, magnesium or calcium salt. Gluconic acid can also be used "as such" or in the form of a salt.
[0026] Typically, in the composition of the present invention, the weight percentage of butyric acid or its salt ranges from 5% to 90%; preferably 10% to 70%; more preferably 40% to 60%, and the weight percentage of gluconic acid ranges from 0.1% to 8%; preferably 0.6% to 5%; more preferably 0.7% to 4%.
[0027] The dosage unit of butyric acid or its salt may be 100 mg-1,500 mg; preferably 200-1,000 mg; more preferably 400 mg-500 mg, while the range of gluconic acid may be 5 mg-90 mg; preferably 10 mg-60 mg; more preferably 20 mg-40 mg.
[0028] In addition to butyric acid and gluconic acid, the composition may also contain other ingredients, such as vitamins (A, B group, C, D, E, K), minerals (magnesium, potassium, zinc, iron, calcium, copper, manganese, selenium), plant-based ingredients (extracts, powdered spices, ferments, oils, essential oils, polyphenols, bioflavonoids), fungi in extract or powder form, algae in extract or powder form, other substances with nutritional and / or physiological effects (e.g. lipoic acid, melatonin, resveratrol, GABA, coenzyme Q10, choline), essential and non-essential amino acids. The sum of the other ingredients is typically 1%-15% w / w.
[0029] The compositions of the present invention may be formulated using conventional techniques and excipients into various forms suitable for oral, rectal, buccal or parenteral administration.
[0030] Examples of such forms include functional foods, foods for special medical purposes, food or dietary supplements, pharmaceutical forms such as tablets, hard or soft capsules, granules, solutions, suspensions, vaginal suppositories, suppositories, creams, gels, enema suspensions.
[0031] Additives and excipients suitable for the preparation of administration forms with modified release in different intestinal tracts may be used.
[0032] Advantageously, the compositions of the invention produce a surprising increase in anti-inflammatory activity without inducing any undesirable side effects, particularly in the treatment of disorders and syndromes associated with alterations in the intestinal mucosa, gastrointestinal barrier function and dysbiosis, such as irritable bowel syndrome (IBS), chronic inflammatory bowel disease (IBD), diverticular disease, diverticulitis, intestinal infections, celiac disease, food intolerance, food allergies, constipation, diarrhea, intestinal alterations and systemic consequences from the use of antibiotics or other drugs, medical treatments, surgical treatments with intestinal effects or food poisoning.
[0033] The following examples illustrate the invention.
[0034] Examples 1 and 2: Tablets / Coated Tablets
[0035] Tablets can be prepared by direct compression of the ingredients or by compression of their granulated form (dry granulation or wet granulation). The ingredients may advantageously be distributed between two or more layers of the tablet with different ingredient release kinetics.
[0036] Direct Compression
[0037] 1. Accurately weigh all ingredients in separate containers.
[0038] 2. Sieve the pre-weighed ingredients (active ingredient and excipients).
[0039] 3. Mix all ingredients.
[0040] 4. Fill the tablet press die with the mixture prepared in step 3 and form the tablets using appropriate compression force.
[0041] Compression in granular form
[0042] Dry granulation
[0043] 1. Accurately weigh all ingredients to be granulated in separate containers.
[0044] 2. Sieve the pre-weighed ingredients (active ingredient and excipients).
[0045] 3. Mix the ingredients with appropriate pre-weighed reagents (eg binders, diluents, etc.) to facilitate granule formation by compaction and crushing.
[0046] 4. The granules obtained are subjected to an optional sieving step.
[0047] 5. Mix the resulting granules with other ingredients (if any).
[0048] 6. Fill the tablet press die with the mixture prepared in step 5 and form the tablets using appropriate compression force.
[0049] Wet granulation
[0050] 1. Accurately weigh all ingredients to be granulated.
[0051] 2. Optionally sieve the pre-weighed ingredients (active ingredient and excipients).
[0052] 3. The ingredients are mixed with excipients (if any) to be inserted into the frame of the fluid bed granulator.
[0053] 4. Preparation of granulation solution: In a separate container, weigh the binder and / or coating material and disperse them in a suitable solvent to obtain a clear solution.
[0054] 5. Transfer the solution to the granulator and start the granulation process under controlled conditions.
[0055] 6. Carry out a drying step at a controlled temperature (about 50°C ± 5°C) to remove the solvent.
[0056] 7. The granules obtained are subjected to an optional sieving step.
[0057] 8. Mix the resulting granules with other ingredients (if any).
[0058] 9. Fill the tablet press die with the mixture prepared in step 8 and form the tablets using appropriate compression force.
[0059] Preparation of coating layer
[0060] 1. Accurately weigh all coating layer ingredients and the appropriate amount of solvent or solvent mixture.
[0061] 2. Mix the ingredients with the solvent gradually until homogenization is complete.
[0062] 3. Filter the solution through a suitable filter 4. Transfer the tablets to a specific coating pan and start the film coating process under suitable conditions of temperature, pressure and time.
[0063] Example 1
[0064] %w / w <![CDATA[ core ]]> Sodium Butyrate 22.73% Gluconic acid 1.40% Other active ingredients 15.00% Sorbitol 29.26% Microcrystalline Cellulose 21.80% Magnesium Stearate 1.50% Silicon dioxide 1.17% Stearic acid 0.27% Hydroxypropyl methylcellulose 0.01% <![CDATA[ Coating layer ]]> shellac 2.28% Hydroxypropyl methylcellulose 3.13% Microcrystalline Cellulose 0.27% Stearic acid 0.27% Titanium Dioxide 0.41% glycerin 0.30% Mint flavor 0.20% Total film weight 100.00%
[0065] Example 2
[0066] %w / w <![CDATA[ core ]]> Sodium Butyrate 46.05% Gluconic acid 2.75% Other active ingredients 1.76% Sorbitol 24.41% Microcrystalline Cellulose 14.84% Magnesium Stearate 1.47% Silicon dioxide 1.15% Stearic acid 0.26% Hydroxypropyl methylcellulose 0.01% <![CDATA[ Coating layer ]]> shellac 2.24% Hydroxypropyl methylcellulose 2.49% Magnesium carbonate 1.08% Calcium phosphate 0.68% Microcrystalline Cellulose 0.09% Stearic acid 0.09% glycerin 0.30% Mint flavor 0.33% Total weight 100.00%
[0067] Example 3: Hard Capsules
[0068] Capsules can be prepared by filling the shell directly with the ingredients in powder form or in granular or microgranular form (obtained by dry or wet granulation).
[0069] 1. Accurately weigh all ingredients (active ingredient, excipients) in fine powder form or in granular or microgranular form.
[0070] 2. Mix all ingredients.
[0071] 3. Fill the capsule with the mixture obtained in step 2 and close it.
[0072] 4. Pack the capsules after favorable results of consistency control.
[0073] %w / w Sodium Butyrate 41.67% Gluconic acid 2.49% Other active ingredients 4.18% Hydrogenated palm oil 10.42% Dicalcium phosphate 21.91% Magnesium Stearate 2.00% Silicon dioxide 1.00% capsule 16.33% Total capsules 100.00%
[0074] Example 4: Sachets / stick packs containing water dispersible and / or orodispersible powders and / or granules
[0075] The ingredients in powder form and / or in granular or microgranular sub-form are dispensed directly into the sachets / stick packs.
[0076] 1. Accurately weigh all ingredients (active ingredients, excipients).
[0077] 2. Mix all ingredients.
[0078] 3. Fill the preformed packages of sachets or stick packs with the mixture obtained in step 3.
[0079] 4. Packing of sachets or stick packs after favorable results of consistency control.
[0080]
[0081]
[0082] Example 5: Soft Capsules
[0083] Before the capsule filling process begins, two preparation processes are usually carried out simultaneously but separately, leading to the formation of the two parts of the soft capsule, namely, the preparation of (1) the gel mass and (2) the matrix used as the filler for the capsule.
[0084] 1. Preparation of gel pellets
[0085] a. Dissolve pre-weighed gelatin in water at about 80°C under vacuum, then add a plasticizer (eg glycerol).
[0086] b. When the gelatin is completely dissolved, add other pre-weighed ingredients such as colorants, opacifiers and flavoring substances.
[0087] c. The hot gelatin mass is transferred in two separate strips, each about 150 mm long, where they undergo a sol-gel transition of controlled thickness due to cooling. Each strip provides half of a softgel capsule, and each half is transferred to a capsule filling system.
[0088] 2. Preparation of liquid filling matrix
[0089] a. Accurately weigh all ingredients (active ingredient, excipients), including liquid carrier.
[0090] b. Sieve the pre-weighed ingredients to ensure that their particle size does not exceed 200 μm.
[0091] c. Mix / disperse the sieved ingredients in the liquid carrier using a homogenizer-mixer.
[0092] 3. Inject a precisely measured volume of liquid filler into the space between the two gelatin strips at a temperature of about 40° C. Seal the two capsule halves by applying heat and pressure.
[0093] 4. The capsules thus formed were placed in a desiccator and passed through an air dryer having a relative humidity of 20%.
[0094] 5. Packing is done after good results of consistency control.
[0095] %w / v Calcium Butyrate 13.33% Gluconic acid 0.80% Other active ingredients 14.83% Lecithin 2.40% glycerin 49.68% glycerin 18.74% Iron Oxide 0.22% Total weight of soft capsules 100.00%
[0096] Example 6: Solution / suspension
[0097] Depending on the solubility of each component, the components are dispersed in an aqueous or non-aqueous liquid phase to produce a solution or suspension. It is contemplated that the solution can be used for oral or parenteral administration.
[0098] 1. Accurately weigh all ingredients (active ingredients, excipients).
[0099] 2. Dissolved / dispersed in an aqueous or non-aqueous liquid carrier, usually in increasing order of solubility of the ingredients.
[0100] 3. Packed in suitable container after having good results of consistency control.
[0101] %w / v Sodium Butyrate 23,81% Gluconic acid 1,42% Other active ingredients 5,00% Honey 13,89% glycerin 37,30% essence 0,56% water 18,02% Total weight of solution 100,00%
[0102] Example 7: Evaluation of anti-inflammatory properties
[0103] In order to evaluate their anti-inflammatory properties, the compounds constituting the object of the present invention were examined individually and in combination using experimental models. In the studies described, the following active ingredients and combinations were compared using a reconstructed human intestinal tissue model to evaluate their efficacy in modulating intestinal inflammatory responses:
[0104] -Calcium butyrate
[0105] -Gluconic acid
[0106] -Gluconate + Calcium Butyrate
[0107] The determination of proinflammatory cytokines TNF-a and IL-6 was evaluated. The biological model used in this determination is a model of human intestinal epithelium reconstructed in 3D in vitro, which is composed of intestinal epithelial cells and endothelial cells and fibroblasts of human origin. Using serum-free culture medium, a highly differentiated tissue model is produced at the air-liquid interface in an easy-to-manage culture tissue insert. Ultrastructural analysis shows the presence of tight junctions, and the particles that secrete mucus mimic in vivo tissues. Specific tests and analyses are used to screen the potential biological contaminants of cells used to produce tissue models to ensure the functionality and quality of the tissue. Therefore, the experimental intestinal epithelial model does not contain biological contamination and does not usually show a colony of bacteria or microorganisms. Therefore, all findings of this study must be regarded as completely independent of the effect of bacteria (probiotic effect), whether they belong to normal intestinal bacterial flora, commensal bacteria, pathological or pathogenic bacteria, and therefore also independent of the effect of fiber or other prebiotic substances used by bacteria (prebiotic effect).
[0108] In vitro reconstituted intestinal epithelial tissue was exposed to a stressor of bacterial-derived lipopolysaccharide (LPS) combined with the cytokine TNF-α for 24 hours and simultaneously treated for an additional 24 hours under each experimental condition examined. After a 48-hour experimental period, the culture medium was harvested to measure the proinflammatory cytokines TNF-α and IL-6.
[0109] Each ingredient and mixture selected for treatment was diluted with H2O. An average intestinal volume of 80 ml was taken into account. In particular, the following reference doses were used:
[0110] - Calcium butyrate 500 mg;
[0111] - Gluconate 29.87 mg;
[0112] -gluconic acid + calcium butyrate = 29.87 mg + 500 mg.
[0113] 50 μl of each sample was tested in the tissue model, simulating the following experimental conditions:
[0114] Reference dose;
[0115] The experimental plan involved:
[0116] - untreated tissue (CTR-);
[0117] -Tissues exposed to the pro-inflammatory agents LPS+TNF-α (CTR+);
[0118] - Tissues exposed to the pro-inflammatory agents LPS+TNF-α and treated with butyrate (calcium butyrate);
[0119] - Tissues exposed to the pro-inflammatory agents LPS+TNF-α and treated with gluconic acid;
[0120] - Tissues exposed to the pro-inflammatory agents LPS + TNF-α and treated with a mixture of gluconate + butyrate (calcium butyrate);
[0121] Each test was performed in duplicate. In order to monitor the ability of the test component to inhibit inflammatory response in vitro in a system where inflammatory conditions have been induced, the production of proinflammatory cytokines TNF-α and interleukin 6 (IL-6) was assessed. At the end of the treatment, the culture medium was harvested for TNF-α and IL-6 determination using an ELISA kit. The data obtained were statistically analyzed and compared using a t-test. The changes compared to the positive control were considered significant for p<0.05 and are represented as "*".
[0122] Table 1 and Figure 1 TNF-α levels in CTR-, CTR+ and tissues treated according to the experimental protocol are exemplified in . The results are expressed as mean ± standard deviation (expressed in pg / ml), as % change compared to CTR-, and as anti-inflammatory activity compared to CTR+. Analysis of TNF-α levels showed that treatment with butyrate, gluconate and the mixture (butyrate+gluconate) significantly reduced the release of pro-inflammatory cytokines and, therefore, the inflammatory state in response to the induced stress.
[0123] Table 1
[0124]
[0125] Table 2 and Figure 2 IL-6 levels in CTR-, CTR+ and tissues treated according to the experimental protocol are exemplified in . The results are expressed as mean ± standard deviation (expressed in pg / ml), as % change compared to CTR-, and as anti-inflammatory activity compared to CTR+. Analysis of IL-6 levels showed that treatment with butyrate, gluconate and the mixture (butyrate + gluconate) significantly reduced the release of pro-inflammatory cytokines and, therefore, the inflammatory state in response to the induced stress.
[0126] Table 2
[0127]
[0128] The tests performed clearly demonstrate the anti-inflammatory effect of butyrate, as described in the literature. Gluconate is known for its prebiotic effect and the resulting benefits to the intestinal flora and the host. No other effects have been demonstrated or presumed. The tests performed clearly demonstrate the anti-inflammatory effect of the main gluconic acid, which is not secondary to and / or dependent on the prebiotic effect, since the in vitro model does not represent bacterial populations or those normally present in the human or animal intestine, or any kind of pathogens or contaminants, whether viral or fungal. Therefore, the observed effect is unexpected. The anti-inflammatory effect of the butyrate + gluconic acid mixture is surprising; as shown in bold in Tables 1 and 2, it is superior to the effect of the individual components, whose effect is not obvious, since interferences in this specific range have been recorded.
[0129] References
[0130] · Asano T, Yuasa K, Kunugita T, Teraji T, Mitsuoka T. Effects of gluconicacid on human faecal bacteria. Microbial Ecology in Health and Disease v0l. 7: 247-256 (1994).
[0131] ·Fu
[0132] · Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 2000 Apr; 118(4): 724-34.
[0133] · Kameue, C., Tsukahara, T., Yamada, K., Koyama, H., Iwasaki, Y., Nakayama, K., and Ushida, K., Dietary sodium gluconate protects rats from large bowel cancer by stimulating butyrate production. J. Nutr., 134, 940 - 944 (2004).
[0134] · Kameue, C., Tsukahara, T., Ushida, K., Alteration 0f gene expression in the colon of colorectal cancer model rat by dietary sodium gluconate. Biosci Biotechnol Biochem. 2006 Mar;70(3):606 - 14.
[0135] · Koh A, De Vadder F, Kovatcheva - Datchary P, F. From Dietary Fiber to Host Physiology: Short - Chain Fatty Acids as Key Bacterial Metabolites. Cell. June 2, 2016;165(6):1332 - 1345.
[0136] · J, Wells J, Cani PD, García - Ródenas CL, MacDonald T, Mercenier A, Whyte J, Troost F, Brummer RJ. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. October 20, 2016;7(10):e196.
[0137] · Krumbeck JA, Rasmussen HE, Hutkins RW, et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018;6(1):1-16.
[0138] · Salminen S, Collado MC, End0 A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, Vinderola G. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope 0f postbiotics. Nat Rev Gastroenterol Hepatol. September 2021;18(9):649-667.
[0139] · Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632-1640.
[0140] · Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, Vinderola G. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and Scope of postbiotics. Nat Rev Gastroenterol Hepatol. September 2021; 18(9): 649 - 667.
[0141] · Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH, Lee JR, Offermanns S, Ganapathy V. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. January 16, 2014; 40(1): 128 - 39.
[0142] · Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. May 2019; 25(5): 716 - 729.
[0143] · Tsukahara, T., Koyama, H., Okada, M. and Ushida, K., Stimulation of butyrate production by gluconic acid in batch culture of pig cecal digesta and identification of butyrate - producing bacteria. J. Nutr., 132, 2229 - 2234 (2002).
Claims
1. A pharmaceutical or nutritional composition comprising butyric acid or a salt thereof and gluconic acid in a weight ratio of 4:1-60:1, preferably 10:1-25:1; more preferably 11:1-23:
1.
2. A composition according to claim 1, wherein the butyric acid is in the form of a sodium, potassium, magnesium or calcium salt.
3. The composition according to any one of claims 1-2, wherein the weight percentage of butyric acid or its salt is 5%-90%; preferably 10%-70%; more preferably 40%-60%.
4. The composition according to any one of claims 1 to 3, wherein the weight percentage of gluconic acid is 0.1% to 8%; preferably 0.6% to 5%; more preferably 0.7% to 4%.
5. The composition according to any one of claims 1 to 4, comprising 100 mg to 1,500 mg per dosage unit of butyric acid or a salt thereof; preferably 200 mg to 1,000 mg; more preferably 400 mg to 500 mg.
6. A composition according to any one of claims 1 to 5, comprising 5 mg to 90 mg of gluconic acid per dosage unit; preferably 10 mg to 60 mg; more preferably 20 mg to 40 mg.
7. A composition according to any one of claims 1 to 6, further comprising one or more ingredients selected from the group consisting of vitamins, minerals, herbal derivatives in extract or powder form, ferments, oils, essences, polyphenols, bioflavonoids, fungi in extract or powder form; algae in extract or powder form; lipoic acid, melatonin, resveratrol, GABA, coenzyme Q10, choline and amino acids.
8. A composition according to any one of claims 1 to 7 in the form of a tablet, hard or soft capsule, granules, solution, suspension, vaginal suppository, suppository, cream, gel or enema suspension.
9. A composition according to claims 1-8 for use in the treatment of inflammatory bowel disease.
10. A composition for use according to claim 9 for the treatment of chronic inflammatory bowel disease, irritable bowel syndrome, diverticular disease and diverticulitis, intestinal changes and disorders due to drug or antibiotic treatment, intestinal infections, leaky gut syndrome and food intolerance.
